When the FDA added information about progressive multifocal leukoencephalopathy (PML) to the label of Biogen's Tecfidera last year, only one patient on the oral MS-fighter had developed the rare brain disease. Now, the Massachusetts company has confirmed another case, though this one--unlike the last--was nonfatal, a spokeswoman told MedPage Today. Story | More